Bryan Garnier - BIONTECH (BNTX.O) BIONTECH: Boost of confidence in COVID-19 vaccine with additional data and US supply agreement | BUY | USD93 vs. USD62.5 (-11%)

Report

Bryan Garnier

Olga Smolentseva

BIONTECH: Boost of confidence in COVID-19 vaccine with additional data and US supply agreement | BUY | USD93 vs. USD62.5 (-11%)

BIONTECH - BUY | USD93 vs. USD62.5 (-11%)
Boost of confidence in COVID-19 vaccine with additional data and US supply agreement

US government endorses BioNTechâ€™s COVID-19 vaccine
Clinical update reinforces our confidence in BNT162
Differentiated immunogenic activity highlights potential of BioNTechâ€™s platform
Raising FV based on the premium vaccine price and PoS increase

23/07/2020 5 EN

Underlying

BIONTECH

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Olga Smolentseva

Other Reports on these Companies

Bryan Garnier

BIONTECH - BUY | USD308 While minimally disclosed, clinical data support preclinical evidence for BA.4/5 booster

October 14, 2022 October 14, 2022 1 EN

Bryan Garnier

BIONTECH: ESMO late-breaking presentation to substantiate the CAR-T case | BUY | USD308

BIONTECH - BUY | USD308 ESMO late-breaking presentation to substantiate the CAR-T case

September 8, 2022 September 8, 2022 1 EN

Bryan Garnier

BIONTECH - BUY | USD308 Omicron-adapted booster sets a precedent for EUA approval based on preclinical data

FDA approves bivalent booster setting the precedent of preclinical data use Another lawsuit targeting mRNA technology, but we do not expect a significant impact on net revenues

September 1, 2022 September 1, 2022 1 EN

H&M: modest signs of improvement

While still showing a contraction YoY, Q2 margins improved sequentially versus Q1, lending more credibility to the company’s guidance for a positive inflexion point expected in H2 2025. However, H&M remains particularly sensitive to fluid external factors such as promotional activity, freight c

June 27, 2025 June 27, 2025 1 EN

Cédric Rossi

Cédric Rossi

Emerging consolidator in Germany’s optical retail sector

After announcing its ambition to enter the optical sector earlier this month, the German software company The Platform Group (TPG) has already acquired four optical players in Germany. In addition to joining TPG’s MyGlasses.de online platform to implement an omnichannel approach, these acquisitions

June 26, 2025 June 26, 2025 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Avantium: multi-year capacity reservation with Royal Hordijk

This morning, Avantium announced a multi-year capacity reservation agreement (CRA) with Royal Hordijk to supply PEF from its future license network. This deal gives Royal Hordijk preferred access to PEF volumes for making trays and injection-moulded packaging in food, cosmetics and other consumer-g

June 25, 2025 June 25, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BIONTECH: Boost of confidence in COVID-19 vaccine with additional data and US supply agreement | BUY | USD93 vs. USD62.5 (-11%)

BIONTECH - BUY | USD308 While minimally disclosed, clinical data support preclinical evidence for BA.4/5 booster

BIONTECH: ESMO late-breaking presentation to substantiate the CAR-T case | BUY | USD308

BIONTECH - BUY | USD308 Omicron-adapted booster sets a precedent for EUA approval based on preclinical data

H&M: modest signs of improvement

Emerging consolidator in Germany’s optical retail sector

Avantium: multi-year capacity reservation with Royal Hordijk

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe